Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models
出版年份 2021 全文链接
标题
Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-12-21
DOI
10.3389/fphar.2021.761855
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Effects of SGLT2 Inhibitors on Lipid Metabolism
- (2021) Zsolt Szekeres et al. Metabolites
- Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
- (2021) Giovanna Castoldi et al. ACTA DIABETOLOGICA
- The tubular hypothesis of nephron filtration and diabetic kidney disease
- (2020) Volker Vallon et al. Nature Reviews Nephrology
- Mechanisms Leading to Differential Hypoxia Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
- (2020) Milton Packer AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
- (2020) Volker Vallon et al. Annual Review of Physiology
- Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia
- (2019) Jie Zhang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- How do Kidneys Adapt to a Deficit or Loss in Nephron Number?
- (2019) Hadi Fattah et al. PHYSIOLOGY
- Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
- (2019) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats
- (2019) Sua Kim et al. HYPERTENSION RESEARCH
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardioprotection conferred by SGLT2 inhibitors: a renal proximal tubule perspective
- (2019) Danúbia Silva dos Santos et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Genetic ablation and pharmacological inhibition of immunosubunit β5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice
- (2019) Hua-Jun Cao et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Failure to confirm a sodium–glucose cotransporter 2 inhibitor‐induced hematopoietic effect in non‐diabetic rats with renal anemia
- (2019) Daisuke Yamazaki et al. Journal of Diabetes Investigation
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
- (2018) Noha A. T. Abbas et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-Nephron Glomerular Filtration Rate in Healthy Adults
- (2017) Aleksandar Denic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression profiling and immunolocalization of Na+-d-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats
- (2017) Ivana Vrhovac Madunić et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Hyperfiltration-associated biomechanical forces in glomerular injury and response: Potential role for eicosanoids
- (2017) Mukut Sharma et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- The effect of dapagliflozin on renal function in patients with type 2 diabetes
- (2016) Donald Elliott Kohan et al. JOURNAL OF NEPHROLOGY
- Natriuretic Peptide Receptor Guanylyl Cyclase-A in Podocytes is Renoprotective but Dispensable for Physiologic Renal Function
- (2016) Janina Staffel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Salt accelerates aldosterone-induced cardiac remodeling in the absence of guanylyl cyclase-A signaling
- (2016) Hitoshi Nakagawa et al. LIFE SCIENCES
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
- (2016) Yanling Zhang et al. PLoS One
- Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
- (2016) Yoon-Kyung Chang et al. PLoS One
- Concurrent Activation of Multiple Vasoactive Signaling Pathways in Vasoconstriction Caused by Tubuloglomerular Feedback: A Quantitative Assessment
- (2015) Jurgen Schnermann Annual Review of Physiology
- Deoxycorticosterone Acetate/Salt–Induced Cardiac But Not Renal Injury Is Mediated By Endothelial Mineralocorticoid Receptors Independently From Blood PressureNovelty and Significance
- (2015) Achim Lother et al. HYPERTENSION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats
- (2015) Sarika Kapoor et al. PLoS One
- Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search